Ticarcillin-clavulanic acid plus amikacin versus ceftazidime plus amikacin in the empirical treatment of fever in acute leukemia: a prospective randomized trial.

Abstract	We evaluated the efficacy of ticarcillin-clavulanic acid plus amikacin (TCA) with ceftazidime plus amikacin (CFA) as empiric therapy of fever in acute leukemia in a total of 127 episodes. The overall success rate of the therapy (survival) was 93% in TCA group and 92% in CFA group. Success without therapy modifications (afebrile at 72 hours) was 39% for TCA, 31% for CFA; success with modifications was 55% and 61% respectively. Failure (death due to documented or presumed infection) was 6% for TCA and 8% for CFA. Differences were not statistically significant. The success without modifications was higher in the group of patients with fever of unknown origin (FUO) than in documented infections (DI), mainly with CFA. No differences were documented in the resistance rate and in clinical outcome during severe neutropenia (ANC <100 microl). In our experience TCA is as effective as CFA as first-line treatment in severe neutropenic patients with acute leukemia, although in both regimens patients with DI are likely to require modifications in treatment.
Authors	R Fanci, C Paci, F Leoni, C Casini, G Longo
Journal	Journal of chemotherapy (Florence, Italy) (J Chemother) Vol. 15 Issue 3 Pg. 253-9 (Jun 2003) ISSN: 1120-009X [Print] England
PMID	12868552 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References	Clavulanic Acids Amikacin ticarcillin-clavulanic acid Ceftazidime Ticarcillin
Topics	Adult Aged Amikacin (administration & dosage) Ceftazidime (administration & dosage) Chi-Square Distribution Clavulanic Acids (administration & dosage) Dose-Response Relationship, Drug Drug Administration Schedule Drug Therapy, Combination (administration & dosage) Female Fever (drug therapy, etiology, mortality) Follow-Up Studies Humans Leukemia, Myeloid, Acute (complications, diagnosis, mortality) Male Middle Aged Neutropenia (drug therapy, etiology, mortality) Probability Prospective Studies Risk Assessment Survival Rate Ticarcillin (administration & dosage) Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!